Cargando…
Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas
Background Despite improved screening techniques, diagnosis of lung cancer is often late and its prognosis is poor. In the present study, in vitro chemosensitivity of solid tumours and pleural effusions of lung adenocarcinomas were analysed and compared with clinical drug response. Methods Tumour ce...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292226/ https://www.ncbi.nlm.nih.gov/pubmed/32527872 http://dx.doi.org/10.1136/bmjresp-2019-000505 |
_version_ | 1783546066602295296 |
---|---|
author | Papp, Emoke Steib, Anita Abdelwahab, Elhusseiny MM Meggyes-Rapp, Judit Jakab, Laszlo Smuk, Gabor Schlegl, Erzsebet Moldvay, Judit Sárosi, Veronika Pongracz, Judit E |
author_facet | Papp, Emoke Steib, Anita Abdelwahab, Elhusseiny MM Meggyes-Rapp, Judit Jakab, Laszlo Smuk, Gabor Schlegl, Erzsebet Moldvay, Judit Sárosi, Veronika Pongracz, Judit E |
author_sort | Papp, Emoke |
collection | PubMed |
description | Background Despite improved screening techniques, diagnosis of lung cancer is often late and its prognosis is poor. In the present study, in vitro chemosensitivity of solid tumours and pleural effusions of lung adenocarcinomas were analysed and compared with clinical drug response. Methods Tumour cells were isolated from resected solid tumours or pleural effusions, and cryopreserved. Three-dimensional (3D) tissue aggregate cultures were set up when the oncoteam reached therapy decision for individual patients. The aggregates were then treated with the selected drug or drug combination and in vitro chemosensitivity was tested individually measuring ATP levels. The clinical response to therapy was assessed by standard clinical evaluation over an 18 months period. Results Based on the data, the in vitro chemosensitivity test results correlate well with clinical treatment response. Conclusions Such tests if implemented into the clinical decision making process might allow the selection of an even more individualised chemotherapy protocol which could lead to better therapy response. |
format | Online Article Text |
id | pubmed-7292226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-72922262020-06-16 Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas Papp, Emoke Steib, Anita Abdelwahab, Elhusseiny MM Meggyes-Rapp, Judit Jakab, Laszlo Smuk, Gabor Schlegl, Erzsebet Moldvay, Judit Sárosi, Veronika Pongracz, Judit E BMJ Open Respir Res Lung Cancer Background Despite improved screening techniques, diagnosis of lung cancer is often late and its prognosis is poor. In the present study, in vitro chemosensitivity of solid tumours and pleural effusions of lung adenocarcinomas were analysed and compared with clinical drug response. Methods Tumour cells were isolated from resected solid tumours or pleural effusions, and cryopreserved. Three-dimensional (3D) tissue aggregate cultures were set up when the oncoteam reached therapy decision for individual patients. The aggregates were then treated with the selected drug or drug combination and in vitro chemosensitivity was tested individually measuring ATP levels. The clinical response to therapy was assessed by standard clinical evaluation over an 18 months period. Results Based on the data, the in vitro chemosensitivity test results correlate well with clinical treatment response. Conclusions Such tests if implemented into the clinical decision making process might allow the selection of an even more individualised chemotherapy protocol which could lead to better therapy response. BMJ Publishing Group 2020-06-10 /pmc/articles/PMC7292226/ /pubmed/32527872 http://dx.doi.org/10.1136/bmjresp-2019-000505 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Lung Cancer Papp, Emoke Steib, Anita Abdelwahab, Elhusseiny MM Meggyes-Rapp, Judit Jakab, Laszlo Smuk, Gabor Schlegl, Erzsebet Moldvay, Judit Sárosi, Veronika Pongracz, Judit E Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas |
title | Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas |
title_full | Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas |
title_fullStr | Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas |
title_full_unstemmed | Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas |
title_short | Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas |
title_sort | feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas |
topic | Lung Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292226/ https://www.ncbi.nlm.nih.gov/pubmed/32527872 http://dx.doi.org/10.1136/bmjresp-2019-000505 |
work_keys_str_mv | AT pappemoke feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas AT steibanita feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas AT abdelwahabelhusseinymm feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas AT meggyesrappjudit feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas AT jakablaszlo feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas AT smukgabor feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas AT schleglerzsebet feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas AT moldvayjudit feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas AT sarosiveronika feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas AT pongraczjudite feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas |